Skip to content Skip to footer
Subscribe Now
Merck Animal Health
NEWS

Merck Animal Health’s Mometamax Single Receives the US FDA’s Approval to Treat Dogs with Otitis Externa

Shots:The US FDA has approved Mometamax Single (gentamicin, posaconazole, & mometasone furoate otic suspension) to treat otitis externa in dogs; commercially available by the summer of 2025Mometamax Single has shown favorable efficacy, with 80.5% resolution of clinical signs in dogs vs 19.6% with PBOMometamax Single is a single-dose in-clinic treatment for otitis…
May 5, 2025

Read more

Merck Animal Health & AmacaThera
NEWS

Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use

Shots:Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary useCollaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug deliveryAmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force…
May 2, 2025

Read more

Vivani Medical & Okava
NEWS

Vivani Medical & Okava Pharmaceuticals Extend Collaboration to Develop OKV-119 for Canine Cardiometabolic Diseases

Shots:Vivani Medical & Okava Pharmaceuticals have expanded their 2019 collaboration to develop OKV-119 for cardiometabolic conditions in dogs, which initially focused on catsFinancial terms of the expanded agreement remain undisclosed but incl. future milestones & royalty payments to VivaniOKV-119 (GLP-1 receptor agonists) uses Vivani’s NanoPortal tech for steady drug delivery over time from…
April 16, 2025

Read more

OS Therapies
NEWS

OS Therapies Reports Clinical Data of OST-HER2 for the Treatment of Unresected Osteosarcoma in Dogs

Shots:OS Therapies has reported data from 2 studies assessing OST-HER2 with palliative radiation to prevent or delay amputation in dogs with unresected appendicular osteosarcomaUnpublished data showed tumor arrest, delayed metastases, & >500-day survival in 5/15 dogs while data published Molecular Therapy, showed early immune response from the 1st dose, with short-term survivors with…
April 11, 2025

Read more

Spirited Paw
NEWS

Spirited Paw Launches Calm Chewable Wafers for Dogs and Cats

Shots:Spirited Paw (Standard Process' Brand) has launched Calm supplement to manage stress-related behaviors like occasional anxiety in cats & dogsCalm consists of scientifically-backed ingredients along with plant-based nutrients like Kalette, ginger & chamomile extracts, grown on Standard Process’ 868-acre USDA-certified organic farm  Calm contains L-Theanine, L-Tryptophan, & marine-derived Magnesium, with L-Theanine tested in…
March 31, 2025

Read more

NEWS

Kemin Industries Launches Prosidium to Improve Biosecurity in Animal Feed Industry & Supply

Shots:Kemin Industries has launched Prosidium to improve biosecurity in animal feed and global food supplyProsidium is based on peroxy acids, which disrupts pathogen cell membranes to reduce Salmonella risk & viral transmission in animal feed, while the residual acids offer continuous feed protectionAdditionally, Prosidium’s ingredients are approved by various regulatory bodies incl.…
March 17, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (March 10, 2025 – March 13, 2025)  

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars & Animal Health. Check out our full report below:  Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 2025 Read More: Incyte Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at…
March 13, 2025

Read more

Kemin
NEWS

Kemin Industries Launches Prosidium to Improve Biosecurity in Animal Feed Industry & Supply

Shots:Kemin Industries has launched Prosidium to improve biosecurity in animal feed and global food supply Prosidium is based on peroxy acids, which disrupts pathogen cell membranes to reduce Salmonella risk & viral transmission in animal feed, while the residual acids offer continuous feed protection Additionally, Prosidium’s ingredients are approved by various regulatory…
March 13, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (March 03, 2025 – March 07, 2025) 

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & DigiHealth. Check out our full report below:  GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025 Read More: GSK Daiichi Sankyo Reports Interim Data of P-III (DESTINY-Gastric04) Study…
March 7, 2025

Read more

Load more